Targeting DNA topoisomerase II in cancer chemotherapy

被引:1366
作者
Nitiss, John L. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Med Pharmacol, Memphis, TN 38105 USA
关键词
DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; END-JOINING PATHWAYS; RECEPTOR-ALPHA GENES; SACCHAROMYCES-CEREVISIAE; COVALENT COMPLEXES; CELL-CYCLE; HOMOLOGOUS RECOMBINATION;
D O I
10.1038/nrc2607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent molecular studies have expanded the biological contexts in which topoisomerase 11 (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation. Although the biological functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy. The molecular tools that have allowed an understanding of the biological functions of TOP2 are also being applied to understanding the details of drug action. These studies promise refined targeting of TOP2 as an effective anticancer strategy.
引用
收藏
页码:338 / 350
页数:13
相关论文
共 169 条
  • [1] Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage
    Adachi, N
    Iiizumi, S
    Koyama, H
    [J]. DNA AND CELL BIOLOGY, 2005, 24 (06) : 388 - 393
  • [2] Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193 - Implications for the repair of topoisomerase II-mediated DNA damage
    Adachi, N
    Suzuki, H
    Iiizumi, S
    Koyama, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (38) : 35897 - 35902
  • [3] Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage
    Adachi, N
    Iiizumi, S
    So, S
    Koyama, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 318 (04) : 856 - 861
  • [4] Catalytic inhibitors of DNA topoisomerase II
    Andoh, T
    Ishida, R
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3): : 155 - 171
  • [5] Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells
    Aratani, Y
    Andoh, T
    Koyama, H
    [J]. MUTATION RESEARCH-DNA REPAIR, 1996, 362 (02): : 181 - 191
  • [6] Armstrong Michael B, 2008, J Exp Ther Oncol, V7, P135
  • [7] Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer
    Arriola, Edurne
    Moreno, Abelardo
    Varela, Mar
    Serra, Jose M.
    Falo, Catalina
    Benito, Enrique
    Escobedo, Agustin P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (17) : 2954 - 2960
  • [8] CAMPTOTHECIN, A SPECIFIC INHIBITOR OF TYPE-I DNA TOPOISOMERASE, INDUCES DNA BREAKAGE AT REPLICATION FORKS
    AVEMANN, K
    KNIPPERS, R
    KOLLER, T
    SOGO, JM
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (08) : 3026 - 3034
  • [9] Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and γ radiation
    Ayene, IS
    Ford, LP
    Koch, CJ
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 529 - 536
  • [10] Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
    Azarova, Anna M.
    Lyu, Yi Lisa
    Lin, Chao-Po
    Tsai, Yuan-Chin
    Lau, Johnson Yiu-Nam
    Wang, James C.
    Liu, Leroy F.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) : 11014 - 11019